Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

Nature Communications

Volumn 1, Issue 7, 2010, Pages

  Ogawa, Yasushi ^a,d   Nonaka, Yosuke ^a,b   Goto, Toshiyasu ^a   Ohnishi, Eriko ^a   Hiramatsu, Toshiyuki ^a   Kii, Isao ^a   Yoshida, Miyo ^b   Ikura, Teikichi ^a   Onogi, Hiroshi ^a,b   Shibuya, Hiroshi ^a   Hosoya, Takamitsu ^a   Ito, Nobutoshi ^a   Hagiwara, Masatoshi ^a,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KinoPharma   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCINEURIN; DUAL SPECIFICITY TYROSINE (Y) PHOSPHORYLATION REGULATED KINASE 1A; DUAL SPECIFICITY TYROSINE (Y) PHOSPHORYLATION REGULATED KINASE 1A INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TAU PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; BENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; DYRK KINASE; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; CRYSTAL STRUCTURE; DOWN SYNDROME; EMBRYO; EMBRYO DEVELOPMENT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PROTEIN PHOSPHORYLATION; X RAY CRYSTALLOGRAPHY; XENOPUS LAEVIS; ANIMAL; CELL STRAIN COS1; CELL STRAIN HEK293; CERCOPITHECUS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BENZOTHIAZOLES; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COS CELLS; CRYSTALLOGRAPHY, X-RAY; DOWN SYNDROME; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAU PROTEINS; XENOPUS LAEVIS;

EID: 78650144287     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1090     Document Type: Article

References (58)

1. Becker, W., Weber, Y., Wetzel, K., Eirmbter, K., Tejedor, F. J.& Joost, H. G. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem. 273, 25893-25902 (1998). (Pubitemid 28475820)
2. Wiseman, F. K., Alford, K. A., Tybulewicz, V. L.& Fisher, E. M. Down syndrome-recent progress and future prospects. Hum. Mol. Genet. 18, R75-83 (2009).
3. Sherman, S. L., Allen, E. G., Bean, L. H.& Freeman, S. B. Epidemiology of Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 13, 221-227 (2007). (Pubitemid 47613276)
4. Antonarakis, S. E.& Epstein, C. J. The challenge of Down syndrome. Trends Mol. Med. 12, 473-479 (2006). (Pubitemid 44441997)
5. Guimera, J. et al. A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum. Mol. Genet. 5, 1305-1310 (1996). (Pubitemid 26335848)
6. Shindoh, N. et al. Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from 'the Down syndrome critical region' of chromosome 21. Biochem. Biophys. Res. Commun. 225, 92-99 (1996). (Pubitemid 26285401)
7. Song, W. J. et al. Isolation of human and murine homologues of the Drosophila minibrain gene: Human homologue maps to 21q22.2 in the Down syndrome 'critical region'. Genomics 38, 331-339 (1996).
8. Korbel, J. O. et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl Acad. Sci. USA 106, 12031-12036 (2009).
9. Olson, L. E. et al. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum. Mol. Genet. 16, 774-782 (2007). (Pubitemid 47061624)
10. Guimera, J., Casas, C., Estivill, X.& Pritchard, M. Human minibrain homologue (MNBH/DYRK1): Characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57, 407-418 (1999). (Pubitemid 29239228)
11. Liu, F. et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 22, 3224-3233 (2008).
12. Dowjat, W. K. et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 413, 77-81 (2007). (Pubitemid 46149186)
13. Wegiel, J. et al. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta. Neuropathol. 116, 391-407 (2008).
14. Smith, D. J. et al. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet. 16, 28-36 (1997). (Pubitemid 27198153)
15. Branchi, I. et al. Transgenic mouse in vivo library of human Down syndrome critical region 1: Association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J. Neuropathol. Exp. Neurol. 63, 429-440 (2004). (Pubitemid 38669664)
16. Ahn, K. J. et al. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 22, 463-472 (2006).
17. Sebrie, C. et al. Increased dosage of DYRK1A and brain volumetric alterations in a YAC model of partial trisomy 21. Anat. Rec (Hoboken) 291, 254-262 (2008).
18. Laguna, A. et al. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev. Cell 15, 841-853 (2008).
19. Altafaj, X. et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 10, 1915-1923 (2001). (Pubitemid 32910536)
20. Martinez de Lagran, M. et al. Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol. Dis. 15, 132-142 (2004). (Pubitemid 38134388)
21. Altafaj, X. et al. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol. Dis. 32, 377-384 (2008).
22. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600 (2006). (Pubitemid 43927286)
23. Fotaki, V. et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell Biol. 22, 6636-6647 (2002).
24. Fotaki, V., Martinez De Lagran, M., Estivill, X., Arbones, M.& Dierssen, M. Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. Behav. Neurosci. 118, 815-821 (2004). (Pubitemid 38970502)
25. Benavides-Piccione, R. et al. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol. Dis. 20, 115-122 (2005). (Pubitemid 41219208)
26. Arque, G., Fotaki, V., Fernandez, D., Martinez de Lagran, M., Arbones, M. L.& Dierssen, M. Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). PLoS One 3, e2575 (2008).
27. Muraki, M. et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279, 24246-24254 (2004). (Pubitemid 38725286)
28. Mott, B. T. et al. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg. Med. Chem. Lett. 19, 6700-6705 (2009).
29. Bain, J. et al. The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408, 297-315 (2007).
30. Gockler, N., Jofre, G., Papadopoulos, C., Soppa, U., Tejedor, F. J.& Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276, 6324-6337 (2009).
31. Kim, H., Sablin, S. O.& Ramsay, R. R. Inhibition of monoamine oxidase A by ß-carboline derivatives. Arch. Biochem. Biophys. 337, 137-142 (1997). (Pubitemid 27198065)
32. Himpel, S. et al. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem. J. 359, 497-505 (2001). (Pubitemid 33063373)
33. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H.& Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90, 859-869 (1997). (Pubitemid 27381625)
34. Woods, Y. L. et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Be at Ser539 and the microtubule-associated protein tau at Thr212: Potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609-615 (2001). (Pubitemid 32434076)
35. Ryoo, S. R. et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 282, 34850-34857 (2007).
36. Crabtree, G. R.& Olson, E. N. NFAT signaling: Choreographing the social lives of cells. Cell 109 (Suppl), S67-79 (2002). (Pubitemid 34457853)
37. Gwack, Y. et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 441, 646-650 (2006). (Pubitemid 43927297)
38. Fuentes, J. A.& Longo, V. G. An investigation on the central effects of harmine, harmaline and related ß-carbolines. Neuropharmacology 10, 15-23 (1971).
39. Jones, R. T. in Kaplan& Sadock's Comprehensive Textbook of Psychiatry (eds. Sadock, B.J.& Sadock, V.A.) (Lippincott Williams& Wilkins, 2005).
40. Son, S. Y., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E.& Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc. Natl Acad. Sci. USA 105, 5739-5744 (2008). (Pubitemid 351758442)
41. Bain, J., McLauchlan, H., Elliott, M.& Cohen, P. The specificities of protein kinase inhibitors: An update. Biochem. J. 371, 199-204 (2003). (Pubitemid 36458094)
42. Mandel, S. A., Amit, T., Weinreb, O., Reznichenko, L.& Youdim, M. B. Simultaneous manipulation of multiple brain targets by green tea catechins: A potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther. 14, 352-365 (2008).
43. Patra, S. K., Rizzi, F., Silva, A., Rugina, D. O.& Bettuzzi, S. Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): Specificity and interaction with membrane lipid rafts. J. Physiol. Pharmacol. 59 (Suppl 9), 217-235 (2008).
44. Leder, S. et al. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties. Biochem. J. 372, 881-888 (2003). (Pubitemid 36760401)
45. Kao, S. C. et al. Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation. Science 323, 651-654 (2009).
46. Guedj, F. et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 4, e4606 (2009).
47. Noll, C. et al. DYRK1A, a novel determinant of the methionine- homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase. PLoS One 4, e7540 (2009).
48. Gardiner, K. J. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol. Sci. 31, 66-73 (2009).
49. Yu, T. et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum. Mol. Genet 19, 2780-2791.
50. Kimura, R. et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between ß-amyloid production and tau phosphorylation in Alzheimer disease. Hum. Mol. Genet. 16, 15-23 (2007). (Pubitemid 46152541)
51. Ferrer, I. et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol. Dis. 20, 392-400 (2005). (Pubitemid 41476265)
52. Wisniewski, K. E., Wisniewski, H. M.& Wen, G. Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278-282 (1985). (Pubitemid 15136603)
53. Leder, S., Weber, Y., Altafaj, X., Estivill, X., Joost, H. G.& Becker, W. Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. Biochem. Biophys. Res. Commun. 254, 474-479 (1999). (Pubitemid 29290425)
54. Fukuhara, T. et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl Acad. Sci. USA 103, 11329-11333 (2006). (Pubitemid 44156517)
55. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C.& Read, R. J. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007). (Pubitemid 47080256)
56. Brunger, A. T. Version 1.2 of the crystallography and NMR system. Nat. Protoc. 2, 2728-2733 (2007).
57. Hyodo-Miura, J., Urushiyama, S., Nagai, S., Nishita, M., Ueno, N.& Shibuya, H. Involvement of NLK and Sox11 in neural induction in Xenopus development. Genes Cells 7, 487-496 (2002). (Pubitemid 34537773)
58. Satoh, K. et al. Nemo-like kinase-myocyte enhancer factor 2A signaling regulates anterior formation in Xenopus development. Mol. Cell Biol. 27, 7623-7630 (2007). (Pubitemid 350033667)